帶狀皰疹疫苗介紹

水痘帶狀疱疹病毒引起的帶狀疱疹（herpes zoster, HZ）及其最常見的併發症——帶狀疱疹後神經痛（postherpetic neuralgia, PHN），會嚴重影響患者的生活品質，並加重醫療系統的負擔。在台灣，HZ的年發生率約為每千人年4.89例，相關的醫療支出每年高達2.5億至3.19億元新台幣。帶狀疱疹疫苗是預防HZ的有效方法，目前已上市的疫苗包括伏帶疹（Zostavax）和欣剋疹（Shingrix）。伏帶疹為活性減毒疫苗，而欣剋疹則為非活性基因重組疫苗。本篇綜論將分別簡短介紹兩種疫苗——伏帶疹和欣剋疹特性以及在不同族群中的施打保護力和安全性結果。

Varicella-zoster virus (VZV) causes herpes zoster (HZ) and its most common complication, postherpetic neuralgia (PHN), which significantly affects the quality of life of patients and increases the financial burden on healthcare systems. In Taiwan, the annual incidence of HZ is approximately 4.89 cases per 1,000 individuals, with related medical expenses reaching between NT$250–319 million annually. HZ vaccination is an effective prevention method. Two vaccines are currently available: Zostavax and Shingrix. Zostavax is a live attenuated vaccine, whereas Shingrix is a non-live recombinant vaccine. This review briefly introduces the protective efficacy and safety results of Zostavax and Shingrix in different populations.